Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis

Diabetologia, Journal Year: 2023, Volume and Issue: 66(8), P. 1395 - 1412

Published: May 19, 2023

Abstract Aims/hypothesis To provide a systematic overview of the current body evidence on high-risk phenotypes diabetes associated with COVID-19 severity and death. Methods This is first update our recently published living review meta-analysis. Observational studies investigating in individuals confirmed SARS-CoV-2 infection regard to COVID-19-related death were included. The literature search was conducted from inception up 14 February 2022 PubMed, Epistemonikos, Web Science Research Database updated using PubMed alert 1 December 2022. A random-effects meta-analysis used calculate summary relative risks (SRRs) 95% CIs. risk bias evaluated Quality Prognosis Studies (QUIPS) tool certainty GRADE approach. Results total 169 articles (147 new studies) based approximately 900,000 We 177 meta-analyses (83 94 severity). Certainty strengthened for associations between male sex, older age, blood glucose level at admission, chronic insulin use, metformin use (inversely) pre-existing comorbidities (CVD, kidney disease, obstructive pulmonary disease) New moderate high emerged association obesity (SRR [95% CI] 1.18 [1.04, 1.34], n =21 studies), HbA 1c (53–75 mmol/mol [7–9%]: [1.06, 1.32], =8), glucagon-like peptide-1 receptor agonist (0.83 [0.71, 0.97], =9), heart failure (1.33 [1.21, 1.47], =14), liver disease (1.40 [1.17, 1.67], =6), Charlson index (per unit increase: 1.33 [1.13, 1.57], =2), levels C-reactive protein 5 mg/l 1.07 [1.02, 1.12], =10), aspartate aminotransferase U/l 1.28 1.54], =5), eGFR 10 ml/min per 1.73 m 2 0.80 0.90], lactate dehydrogenase 1.03 [1.01, 1.04], =7) lymphocyte count 1×10 9 /l 0.59 [0.40, 0.86], =6) Similar observed COVID-19, some existing vaccination status (0.32 [0.26, 0.38], =3), hypertension (1.23 [1.14, 1.33], =49), neuropathy cancer, IL-6 levels. limitation this study that included are observational nature residual or unmeasured confounding cannot be ruled out. Conclusions/interpretation Individuals more severe course had poorer prognosis than milder disease. Registration PROSPERO registration no. CRD42020193692. Previous version previous can found https://link.springer.com/article/10.1007/s00125-021-05458-8 Funding German Diabetes Center (DDZ) funded by Federal Ministry Health Culture State North Rhine-Westphalia. supported part grant Education (DZD). Graphical

Language: Английский

---

Antidiabetic agent use and clinical outcomes in patients with diabetes hospitalized for COVID-19: a systematic review and meta-analysis

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 6, 2025

The effect of antidiabetic agents on mortality outcomes is unclear for individuals with diabetes mellitus (DM) who are hospitalized COVID-19. To examine the relationship between agent use and clinical in DM A systematic review literature (2020-2024) was performed across five databases. Included articles reported primary research (English) reporting adult patients (≥18 yrs.) receiving were Following PRISMA guidelines underwent independent dual review. Quality appraisal completed included studies. Independent reviewers used a structured data extraction form to retrieve relevant data. Aggregated synthesized by treatment regimen descriptively. Random effects meta-analyses assess relative risk prevalence mortality. After removing duplicates, title abstract screening 4,898 identified 118 full-text 35 retained analysis. primarily from China (15/35, 43%) retrospective nature (31/35, 89%). Fourteen studies (40%) assessed multiple agents, fifteen (42%) focused metformin, three (9%) DPP-4 inhibitors, single investigated insulin, TZD, SGLT2 inhibitors. Despite differences among studies, overall metformin inhibitor users 0.432 (95% CI = 0.268-0.695, z 3.45, p < 0.001) all 16% 13%-19%, 10.70, 0.001). Synthesis findings suggest that remained oral (with/without supplemental insulin therapy) exhibited decreased lower inflammatory markers. Results indicate should continue additional basal as needed improve glycemic control reduce Further work uncover mechanism(s) clarify medical management approaches.

Language: Английский

---

COVID-19 clinical presentation, management, and epidemiology: a concise compendium

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 31, 2025

Coronavirus Disease 2019, caused by severe acute respiratory coronavirus 2, has been an ever-evolving disease and pandemic, profoundly impacting clinical care, drug treatments, understanding. In response to this global health crisis, there unprecedented increase in research exploring new repurposed drugs advancing available interventions treatments. Given the widespread interest topic, review aims provide a current summary-for interested professionals not specializing COVID-19-of characteristics, recommended vaccines, prevention strategies, epidemiology of COVID-19. The also offers historical perspective on pandemic enhance

Language: Английский

---

New Onset Diabetes After COVID 19 (NODAC) is predominantly due to exacerbated Insulin Resistance (IR) rather than beta cell dysfunction: Lessons from tertiary care hospital data during confluence of two epidemics

Endocrine, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 27, 2024

Language: Английский

---

Overview of the cardio-metabolic impact of the COVID-19 pandemic

Endocrine, Journal Year: 2023, Volume and Issue: 80(3), P. 477 - 490

Published: April 27, 2023

Language: Английский

---

Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies

Life, Journal Year: 2022, Volume and Issue: 12(8), P. 1205 - 1205

Published: Aug. 8, 2022

Type 2 diabetes mellitus (T2DM) is one of the world's leading causes death and life-threatening conditions. Therefore, we review complex vicious circle responsible for T2DM risk factors such as western diet, obesity, genetic predisposition, environmental factors, SARS-CoV-2 infection. The prevalence economic burden on societal healthcare systems are dissected. Recent progress diagnosis clinical management T2DM, including both non-pharmacological latest pharmacological treatment regimens, summarized. becoming more new medications approved. This focused non-insulin treatments to reach optimal therapy beyond glycemic management. We experimental findings risks that attributable patients. Finally, shed light recent single-cell-based technologies multi-omics approaches have reached breakthroughs in understanding pathomechanism T2DM.

Language: Английский

---

Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods – United States, 11 December 2020 to 30 June 2022

Vaccine, Journal Year: 2023, Volume and Issue: 41(42), P. 6339 - 6349

Published: Sept. 22, 2023

Language: Английский

---

Impact of COVID-19 on diabetes mellitus outcomes and care in sub-Saharan Africa: A scoping review

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 13, 2024

Abstract Background The COVID-19 pandemic impacted diabetes mellitus clinical outcomes and chronic care globally. However, little is known about its impact in low-resource settings such as sub-Saharan Africa. Hence, to address this, we systematically conducted a scoping review explore the on countries of Methods We applied our search strategy PubMed, Web Science, CINAHL, African Index Medicus, Google Scholar, Cochrane Library, Scopus, Science Direct, ERIC Embase obtain relevant articles published from January 2020 March 2023. Two independent reviewers were involved screening retrieved articles. Data eligible extracted quantitative, qualitative mixed methods studies. Numerical data summarised using descriptive statistics, while thematic framework was used categorise identify themes for data. Results found 42 360 eligible, mainly South Africa, Ethiopia Ghana (73.4%). increased risk death (OR 1.30 – 9.0, 95% CI), hospitalisation 3.30 3.73: severity (OR: 1.30-4.05, CI) persons with mellitus. also developing hospitalised cases. pandemic, other hand, associated disruptions patient self-management routine service delivery. Three major emerged, namely, (i) patient-related health management challenges, (ii) delivery (iii) reorganisation Conclusion mortality morbidity among people living In addition, worsened management. Sub-Saharan should, therefore, institute appropriate policy considerations during widespread emergencies.

Language: Английский

---

Diabetes mellitus in sub-saharan Africa during the COVID-19 pandemic: A scoping review

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(7), P. e0305112 - e0305112

Published: July 8, 2024

Background The COVID-19 pandemic impacted the healthcare and outcomes of individuals with various chronic diseases. However, there is a paucity data on impact diabetes mellitus (DM) in low-resource settings. To address this, we conducted scoping review to explore literature published diabetes-related care during countries sub-Saharan Africa. Methods We applied our search strategy PubMed, Web Science, CINAHL, African Index Medicus, Google Scholar, Cochrane Library, Scopus, Science Direct, ERIC Embase obtain relevant articles from January 2020 March 2023. Two independent reviewers were involved screening retrieved articles. Data eligible extracted quantitative, qualitative mixed-methods studies. Quantitative evidence was summarised using descriptive statistics, while thematic framework used identify categorise themes evidence. Results found 42 360 eligible, mainly South Africa, Ethiopia Ghana (73.4%). incidence DM among cases 13.7/1,000 person-days observation. associated increased odds death (OR 1.30–9.0, 95% CI), hospitalisation 3.30–3.73: severity (OR: 1.30–4.05, CI) persons DM. Challenges caring for inadequate patient self-management, difficulties access, resources. Conclusion characterised by high infected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19-associated mortality, severity, people also created self-management worsened quality services. Policymakers should devise preventive management strategies emerging re-emerging infectious disease epidemics outbreaks, given that such occurrences are increasingly frequent region.

Language: Английский

---

Evaluation of some Hematological and Inflammatory Factors in Iraqi Patients Suffering from COVID-19 and Type 2 Diabetes Mellitus

Al-Mustansiriyah Journal of Science, Journal Year: 2023, Volume and Issue: 34(3), P. 24 - 30

Published: Sept. 30, 2023

COVID-19 is a newly recognized sickness spreading rapidly worldwide and causing many consequences deaths. Diabetes Mellitus(DM) suggested as risk factor that contributes to the severity mortality of COVID-19. The present study investigates levels Lymphocytes, Neutrophils, C-reactive protein, D-dimer, ferritin, in patients who suffer from type 2 diabetes mellitus (T2DM) those without T2DM. 80 participants enrolled this study, distributed into 4 groups; Group 1 (G1) included 20 with T2DM; (G2) comprised COVID-19; 3(G3) T2DM patients. In addition, individuals were taken healthy control group. patient samples obtained Ibn-AlKhateeb Hospital /Baghdad period between February April 2022. A hematology automated device was utilized count lymphocytes neutrophils, while biochemical employed measure CRP, ferritin. Regarding blood immune cells, there significant decrease lymphocyte counts increase neutrophil G1 G2 groups compared serum studying markers(CRP, ferritin )were increased G1, G2, G3 Furthermore, group had higher these markers than other groups, which are considered prognostic for infection.

Language: Английский

---